Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on March 9, 2021. Patrik Jonsson, senior vice president and chief customer officer, will engage in a virtual fireside chat at 9:45 a.m. ET. A live audio webcast will be available on Lilly's Investor website, and a replay will be accessible for about 90 days. Lilly is dedicated to creating high-quality medicines and improving disease management globally. For more information, visit www.lilly.com.

Eli Lilly announced a positive scientific opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for bamlanivimab alone and in combination with etesevimab. These therapies are recommended for treating COVID-19 in patients aged 12 and older at high risk of severe disease, who do not require supplemental oxygen. Data from the BLAZE-1 trial indicated a 70% reduction in hospitalizations. Lilly aims to provide affordable access globally, especially in low- and middle-income countries, while emphasizing that these treatments are not FDA-approved and carry potential risks.

Loxo Oncology at Lilly announced the publication of data from the pirtobrutinib (LOXO-305) global Phase 1/2 BRUIN clinical trial in relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas. Published in The Lancet, findings from the trial demonstrate safety and efficacy across 323 patients. The company plans to initiate four global Phase 3 studies in 2021 to further advance pirtobrutinib’s development, addressing unmet therapeutic needs in patients previously treated with standard care options.

Tirzepatide, from Eli Lilly (NYSE: LLY), demonstrated superior reductions in A1C and body weight compared to semaglutide in the 40-week SURPASS-2 trial involving 1,879 adults with type 2 diabetes. The 15 mg dose of tirzepatide achieved a 2.46% reduction in A1C and a weight loss of 12.4 kg. Notably, 51% of participants on 15 mg reached an A1C below 5.7%, outpacing semaglutide's 20%. Safety profiles were similar, primarily showing gastrointestinal-related adverse events. These results indicate the potential of tirzepatide as a leading treatment option for managing type 2 diabetes.

Eli Lilly and Company and Incyte announced positive top-line results from the BRAVE-AA2 Phase 3 trial for baricitinib in treating severe alopecia areata (AA). Both 2-mg and 4-mg doses showed statistically significant scalp hair regrowth at Week 36 compared to placebo. Baricitinib, designated as Breakthrough Therapy by the FDA, aims to address the unmet needs of AA patients, with no current FDA-approved treatments available. The trial involved 546 diverse participants, with no reported severe adverse events. Detailed results will be presented at upcoming conferences.

The U.S. government has purchased a minimum of 100,000 doses of bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) from Eli Lilly for $210 million to treat mild to moderate COVID-19 in high-risk patients. This follows their emergency use authorization for such treatments. Additional doses may be purchased, totaling up to 1,200,000 units under certain conditions. The NIH recommends these antibodies to help reduce severe COVID-19 cases. The purchase is part of Lilly's ongoing efforts to combat COVID-19 with their neutralizing antibodies.

Welldoc and Eli Lilly have announced a collaboration to integrate Welldoc's BlueStar software into Lilly's connected insulin solutions. This partnership aims to develop an updated version of the BlueStar app, which will include insulin dosing data from multiple Lilly insulins. The app, FDA-cleared for diabetes management, supports insulin titration and integrates monitoring tools. Lilly plans to submit regulatory approvals in 2021 and commercialize the platform in the U.S. This collaboration seeks to enhance diabetes care through innovative technology.

Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41^st Annual Health Care Conference on March 4, 2021, at 9:10 a.m. Eastern Time. Chief Scientific Officer Daniel Skovronsky will engage in a fireside chat during the event. Investors and media can access a live audio webcast through Lilly's Investor website, with a replay available for approximately 90 days post-event. Lilly continues its commitment to healthcare innovation, focusing on developing life-changing medicines for global communities.

Eli Lilly and Rigel Pharmaceuticals have announced a global exclusive license agreement to co-develop Rigel's RIPK1 inhibitor, R552, targeting autoimmune and inflammatory diseases. Lilly will make an upfront payment of $125 million and could pay up to $835 million in milestone payments, plus royalties. R552 has completed Phase 1 trials and will enter Phase 2 trials in 2021. Lilly will lead clinical development and commercialization efforts, while Rigel retains co-commercialization rights in the U.S. This partnership seeks to advance treatments in both immune and CNS disease areas.